Abstract
Introduction

65
In the last two decades allergic diseases have seen a rise worldwide with 66 children suffering the highest burden of the condition 1 . Food allergies, eczema 67 and asthma are the most common allergic disorders in children [1] [2] . Due to the 68 increasing burden of allergic diseases they are a key focus for public health. 69
70
The Developmental Origins of Health and Diseases theory proposes that 71 development is not dictated by a hard-wired genetic programme, instead the 72 organism responds to the surrounding environment and the risk of many 73 diseases is set during this time 3 . It has become increasingly evident that there 74 is an important role for environmental factors in the onset of complex 75 conditions such as allergic diseases and that the role of fixed genetic variation 76 is far less than previously believed 4 . Therefore, new approaches towards 77 disease prevention with an emphasis on early interventions i.e. pre-pregnancy 78 and/or during pregnancy need to be widely investigated. Current evidence 79
suggests that the role of maternal diet during pregnancy on subsequent 80 disease development is a priority area for future studies 5 , as many of the 81 immune modulatory processes may start in-utero. 82
83
The role of environmental and life-style factors on developing allergies has 84 been examined in a number of epidemiological studies. A systematic review 85 has investigated the association of nutrient deficiencies on the risk of 86 development of asthma and allergic diseases in children 6 . This review 87 included 62 observational studies and indicated that vitamins A, D, and E; 88 zinc; fruits and vegetables; and a Mediterranean diet during pregnancy may 89 prevent asthma and wheeze. However, this review was based on 90 observational studies which carry a high risk of bias and there is a need for 91 secondary research based on summary of more robust interventional studies. 92
93
The purpose of this systematic review is to summarise the existing 94 randomised controlled trials evidence of the association between vitamin 95 supplements during pregnancy and the risk of developing allergic disorders in 96 the offspring. 97
Methods
98
Criteria for considering studies for this review 99
Types of studies 100
Only randomised controlled trials (RCT) (including cluster randomised 101 controlled trials and quasi-randomised controlled trials) with a minimum 102 follow-up of one month postnatally were included. The review considered 103 studies which documented clinical outcome data and used any types of 104 vitamins. No language restriction was applied. 105
Types of participants 106
Pregnant women and their offspring, regardless of their location were 107 considered as the target group for this systematic review. High risk 108 populations were not excluded. 109
Types of interventions 110
Studies that used any vitamin supplementation during pregnancy, irrespective 111 of dose, formulation or mode of delivery and composition e.g. oil, tablet. 112
Trials were also included if the intervention(s) had been extended after 113 pregnancy either during breast-feeding or with the infants or both. 114
Outcomes of interest 115
Trials were included if they had reported clinical outcomes of allergy in the 116 offspring, either as a primary or secondary endpoint. Allergic outcomes were 117 defined as: asthma, wheeze, rhinitis, eczema, food allergy and positive skin 118 prick test (to any allergen) and elevated specific IgE. Outcomes included were 119 those, which had utilised a validated method as opposed to parental reports. 120
Search strategy for identification of studies 121
A comprehensive search strategy, including all the relevant synonyms for the 122 main concepts, was developed covering the main bibliographic databases 123 (online repository). 
Data collection and analysis 143
Selection of studies 144
The main reviewer (MV) screened all the search results against the eligibility 145 criteria and all those which were clearly irrelevant were excluded from further 146 consideration. Thereafter, a tailored eligibility form was used by MV to 147 appraise the retrieved studies, abstract and full text for relevance against the 148 full inclusion criteria. Where there was uncertainty about inclusion of a 149 particular study, other members of the review team (HM & TD) were consulted 150 and a consensus was reached about the study eligibility. All the included 151 studies were discussed and approved by the review team. 152
Data extraction 153
MV extracted the data using a tailored data extraction form (online repository). 154
Detailed information on study characteristics were recorded. Throughout the 155 data extraction process, any disagreements about the interventions and 156 outcomes were discussed and resolved within the review team. There was no 157 blinding to the name of authors, institutions, journals or the outcomes of the 158 trials during the process. Ten percent of all the extracted data was randomly 159 selected and double checked by a second reviewer (HM) for accuracy against 160 the trial reports. 161
Assessment of risk of bias in included studies 162
The risk of bias tool described in the Cochrane Handbook for Systematic 163
Reviews for Interventions was used to appraise the studies 8 . The tool includes 164 seven domains: random sequence generation, allocation concealment, 165 blinding of participants and personnel, blinding of outcome assessments, 166 incomplete outcome data, selective outcome reporting and other bias. 167
Measurement of treatment effect 168
Dichotomous data was analysed as risk ratios or relative risk (RR) with 95% 169 CI and continuous data as mean difference or standardised mean difference, 170 with 95% CI. 171
Unit of analysis issues 172
In trials with more than one intervention arm, multiple pairwise comparisons of 173 intervention groups versus comparator were avoided. Therefore, data from 174 different intervention arms were pooled for an overall comparison with the 175 control or placebo arm. The weight assigned to the control group was 176 considered as the total number of participants in the comparator group versus 177 the total number of participants in the combined intervention arms 9 . 178
Handling missing data 179
All the relevant reported information for the number of missing participants 180 was extracted and if undocumented, this was incorporated into the 181 assessment of risk of bias. No imputed techniques were used for retrieving 182 missing data. 183
Assessment of heterogeneity 184
We used visual inspection of forest plots and also, the Chi 2 test to measure 185 statistical heterogeneity between effect sizes of included studies (P<0.05) 10 . I 2 186 statistics were used to quantify the amount of possible variability in effect 187 estimates that is due to heterogeneity rather than chance (I 2 30 moderate 188 heterogeneity, I
2 ≥75 considerable heterogeneity). 189
Assessment of reporting biases 190
Every effort was made to identify unpublished studies through searching 191 abstracts and ongoing trials databases. Publication bias was assessed using 192 funnel plots 11 . The asymmetry was assessed visually in the plots and no 193 formal statistical tests were conducted. The funnel plot was helpful to explore 194 possible small study biases for some of the primary outcomes (online 195 repository). 196
Data synthesis 197
We used Eppi Reviewer version 4.4.3.0. for conducting meta-analyses using 198 random-effects model. Dichotomous data were entered as events and the 199 number of participants. Data were pooled using random-effects model where 200 heterogeneity was reported as ≤75% 7 . We also reported relative risk as a 201 statistical choice in conducting the meta-analyses, as it is easy to interpret 12 .
202
Studies were grouped under one umbrella as "any vitamins" for performing 203 meta-analyses. 204
Subgroup analysis and investigation of heterogeneity 205
We performed sub-group analyses based on the type of vitamin and type of 206 the control group (i.e. placebo versus no treatment). 207
Sensitivity analysis 208
We did not conduct any sensitivity analysis because of the small number of 209 studies that contributed to meta-analyses. 210
Results
211
The results of the search strategy yielded 341 studies, of which 26 were 212 selected for full-text assessment (Figure1). We included 5 RCTs comparing at 213 least one vitamin with a control that met the inclusion criteria for this 214 systematic review. 215
216
These included trials (including total of 2456 children) were represented by 217 five original papers [13] [14] [15] [16] [17] and four grouped as their companion papers [18] [19] [20] [21] . 218 Table 1 . The 228 most frequently reported outcomes were wheeze and eczema. As expected 229 with systematic reviews there were differences between the included trials in 230 terms of type of the population, supplementation used and the comparators. returned pills. Primarily this study was designed to prevent the risk of fetal 246 growth restriction and premature delivery in the women 18 and the extended 247 follow-up at 2 years has assessed the efficiency of the vitamin intervention on 248 respiratory outcomes in children. 249
250
The list of the reported outcomes in the study is shown in Table 1 . The 251 outcomes of "asthma" and "eczema" are reported at 1-year age and "recurrent 252 
Meta-analyses of vitamin D studies 348
We conducted a meta-analysis for the outcome measure of "recurrent 349 wheeze" for trials that used vitamin D prenatally in pregnant women. Figure 2 
Risk of bias in included trials 360
The risk of bias figures and authors' judgments are presented in online 361
repository. Only one trial was deemed to have low risk of bias across all 362 domains 17 . Of the 5 trials, most had adequate random sequence generation 363 (n=3), allocation concealment (n=3) and performance bias (n=3). All trials 364
were rated as having a low risk of bias for blinding of outcome assessment 365 and selective outcome reporting. Completeness of outcome data was rated as 366 having high risk of bias for one trial 13 since the study had a high loss to follow-367 up and the authors acknowledged the fact that the study was an unplanned 368 extended follow-up of the original trial for measuring allergic outcomes in 369 children. The original trial was primarily designed to assess the efficacy of 370 vitamins C and E supplementation on developing pre-eclampsia in women at 371 increased risk. 372
Discussion
373
This is the first systematic review of randomised controlled trials that 374 investigated the association of prenatal intake of vitamins on the risk of 375 developing allergic/respiratory diseases in the offspring. We identified five 376
RCTs with a total of 2456 children. The studies were of unselected pregnant 377 women 16 , women with a history of atopy 17 , pregnant women at risk of 378 developing pre-eclampsia 13 , different ethnic/race groups 14 and smoking 379 pregnant women 15 . Two studies were judged to have a high risk of bias due to 380 their performance bias [13] [14] or high rate of loss to follow-up 13 . All trials were 381 rated having low risk of bias for blinding of outcome assessment. It was not 382 possible to conduct meta-analyses for vitamin C studies due to observed 383 differences between the included trials. Maternal vitamin D consumption 384 during pregnancy was associated with a lower risk of developing recurrent 385 wheeze in offspring, when compared to placebo/control. However we were 386 not able to investigate the efficiency of vitamin D on other allergic outcomes 387 since outcomes were reported differently in the included trials. In all trials, 388 supplementation with vitamins significantly increased the concentration of 389 vitamins in the intervention group compared to the control group by the end of 390 the intervention. 391
392
Observational studies typically report a beneficial effect of higher intake of 393 vitamin D as well as antioxidants during pregnancy on allergic outcomes [22] [23] .
394
The results from this systematic review proposed a protective effect of 395 prenatal intake of vitamin D during pregnancy for prevention of recurrent 396 wheeze in offspring. However we could not address the effect of prenatal 397 intake of vitamin C or D on other allergic outcomes owing to the observed 398 heterogeneity between the trials. 399
400
It is possible that the follow-up periods of the studies for this review have been 401 too short to detect other allergic outcomes i.e. asthma. For example, 402 wheezing is known as a primary symptom of asthma in early childhood 25 and 403 about 40% of childhood wheeze will persist later in life and will eventually 404 develop into asthma by 6 years of age 26 , indicating majority of wheeze during 405 infancy are in fact acute respiratory infection. Therefore, extended follow-up of 406 these trials could help to provide a clearer answer as to whether the vitamin D 407 intervention is beneficial for asthma prevention. 408
409
There were also some limitations in the studies' design. For example, the 410 trials were statistically underpowered to detect an effect for their primary 411 and/or secondary outcome measures. Significant differences were only 412 observed for some of the secondary outcomes as "at least 1 episode of 413 wheezing" 14 , "episodes of troublesome lung symptoms" 16 and "positive sIgE" Furthermore, studies assessing the efficiency of nutrients are required to 446 consider the defined guidelines in their clinical design enabling to test the 447 associated hypothesis in a valid manner 35 . 448
449
To date, no other systematic review has evaluated the efficacy of prenatal 450 vitamins on the prevention of allergic and/or respiratory outcomes in children. 451
The result from the current evidence is promising that prenatal intake of 452 vitamin D could protect childhood wheeze. The role of maternal consumption 453 of vitamins during pregnancy on the risk of developing other allergic outcomes 454 and sensitisation needs to be investigated in larger well-designed trials. 455
Further it will be important for future research to examine the impact of the 456 timing of the intervention and the optimum dose of vitamins. We were unable 457 to perform any meta-analyses on the timing or dose of intervention and study 458 populations due to the small number of trials that could contribute to meta-459
analyses. 460 461
The current evidence suggests that prenatal intake of daily vitamin D might 462 protect against recurrent childhood wheeze; however there is currently lack of 463 evidence that prenatal intake of vitamins can prevent any other 464 allergic/respiratory outcomes. 465 
